NEW YORK (Reuters Health) Jun 25 – In postmenopausal women with coronary artery disease using hormone replacement therapy (HRT), the factor V Leiden mutation increases the risk of venous thromboembolic events (VTEs), US investigators report.
In fact, “even in women with coronary disease without factor V Leiden, the HRT-associated VTE risk must be carefully considered when HRT is used for approved noncoronary indications,” Dr. David M. Herrington, of Wake Forest University in Winston-Salem, North Carolina, and colleagues warn in the June issue of Arteriosclerosis, Thrombosis and Vascular Biology.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!